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Abstract  
The cognitive and behavioural deficits caused by traumatic brain injury (TBI) to the immature 
brain are more severe and persistent than TBI in the mature brain. Understanding this 
developmental sensitivity is critical as children under four years of age sustain TBI more 
frequently than any other age group. Microglia (MG), resident immune cells of the brain that 
mediate neuroinflammation, are activated following TBI in the immature brain. However, the 
type and temporal profile of this activation and the consequences of altering it are still largely 
unknown.  
In a mouse model of closed head weight drop paediatric brain trauma, we characterized i) 
the temporal course of total cortical neuroinflammation and the phenotype of ex vivo isolated 
CD11B-positive microglia/macrophage (MG/MΦ) using a battery of 32 markers, and ii) 
neuropathological outcome 1 and 5 days post-injury. We also assessed the effects of 
targeting MG/MΦ activation directly, using minocycline a prototypical microglial activation 
antagonist, on these processes and outcome.  
TBI induced a moderate increase in both pro- and anti-inflammatory cytokines/chemokines 
in the ipsilateral hemisphere. Isolated cortical MG/MΦ expressed increased levels of 
markers of endogenous reparatory/regenerative and immunomodulatory phenotypes 
compared with shams. Blocking MG/MΦ activation with minocycline at the time of injury and 
1 and 2 days post-injury had only transient protective effects, reducing ventricular dilatation 
and cell death 1 day post-injury but having no effect on injury severity at 5 days.  
This study demonstrates that, unlike in adults, the role of MG/MΦ in injury mechanisms 
following TBI in the immature brain may not be negative. An improved understanding of 
MG/MΦ function in paediatric TBI could support translational efforts to design therapeutic 
interventions. 
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     1.0 Introduction   
Traumatic brain injury (TBI) is the most common injury leading to significant lifelong disability 
that occurs in children (Stanley et al., 2012). Unfortunately, the cognitive and behavioural 
deficits caused by traumatic brain injury (TBI) to the immature brain are more severe and 
persistent than those observed following comparable injuries to the mature (adult) brain 
(Anderson et al., 2005; Ewing-Cobbs et al., 2006; Hessen et al., 2007; Rivara et al., 2012) 
(reviewed in (Giza et al., 2007)) with injury in an experimental setting progressing into a 
chronic brain disorder (Ajao et al., 2012; Kamper et al., 2013). This is in contrast to 
Kennard’s Principle that the immature brain has superior potential for repair (Bennet et al., 
2013). This is of particular concern as children under the age of four years sustain TBI more 
frequently than any other age group (Koepsell et al., 2011) and in children under the age of 
2 years, the rates of TBI serious enough to require intensive care support are as high as 50 
per 100,000 (Keenan et al., 2003). A developmental sensitivity to TBI as seen in humans is 
also observed in a rodent model of TBI, where within the first 30 days of life, injury is 
maximal when TBI is caused at postnatal day 7 (P7) (Bittigau et al., 1999). In addition, 
during the first three postnatal weeks, rodents display a heightened sensitivity to 
excitotoxicity (Ikonomidou et al., 1999). In mouse and humans this period is when 
developmental processes such as maximal brain growth, synaptogenesis and myelination 
occur. 
In the paediatric population, TBI is caused by injuries and insults, which include 
acceleration/deceleration injuries (shaken baby syndrome) and contusion injuries (direct 
skull impact) (Pinto et al., 2012). Contusion injuries are the prevailing form of non-inflicted 
injuries and also represent a large proportion of inflicted injuries (Pinto et al., 2012). The 
primary injury process in TBI is mechanical damage (i.e. shear forces inducing vascular 
damage and bleeding), followed immediately by mast cell degranulation (Stokely and Orr, 
2008), and secondary pathological processes, including excitotoxicity, ischemia, 
mitochondrial dysfunction, activation of matrix metalloproteinases (MMPs) and activation of 
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caspases leading to apoptosis (Xiong et al., 2013). These secondary injury processes 
induce neuroinflammation, which itself has the potential to be neurotoxic (Hagberg et al., 
2012), but which is poorly understood in the immature brain following TBI.  
Microglia (MG) are the central regulators of neuroinflammation, involved in the pathological 
processes of the majority of acute and chronic brain injuries, such as stroke, Alzheimer’s 
disease and multiple sclerosis (for review see (Prinz et al., 2011)). Thus MG are logical 
candidates to mediate neuropathological changes following TBI in the immature brain. MG 
possess enormous functional plasticity that allows them to participate in both injury and 
repair, as reviewed in (Colton and Wilcock, 2010; Ransohoff and Perry, 2009). The 
nomenclature of these functional activation states (phenotypes) of MG has been simplified to 
facilitate their description and a common nomenclature includes classic pro-inflammatory or 
cytotoxic, anti-inflammatory or reparatory/regenerative and immunomodulatory phenotypes.  
There are specific differences in the immune and inflammatory responses to injury between 
neonatal and adult humans and experimental animals (Copland et al., 2004; Giza et al., 
2007; Schultz et al., 2004; Zhu et al., 2005), including in microglia responsiveness (Butovsky 
et al., 2014). Studies of neuroinflammatory profile and MG activation states have recently 
been published in adult models of TBI (Bye et al., 2007; Kumar et al., 2015) but it is 
unknown how microglia would respond to a similar injury to the developing brain.  As such, 
this study investigates for the first time the characteristics of MG- driven neuroinflammation 
in a mouse model of paediatric TBI. Furthermore, as a proof-of-concept, we aimed to assess 
the effects of modulating MG activity on injury severity using the immunomodulatory 
tetracycline minocycline. Minocycline reportedly has strongly anti-inflammatory actions and 
has been used to reduce MG activation and injury with success in numerous pathological 
models (see Table 1 and review, (Garrido-Mesa et al., 2013)).   
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2.0 Materials and Methods 
2.1 Animals. Study ethics were approved by the Bichat and Robert Debré Hospital ethics 
committee (No 2011-14/676-0050) and adhered to the European Union Guidelines for the 
Care and Use of Animals. Procedures were typically carried out between 10am and 1pm 
(light phase: 7am-7pm daily), all animals were monitored daily during experimentation. A 
single animal represents an experimental unit with groups spread between and across litters 
where possible and each litter had an approximate 50-50% spread of males-females. 
Specifically, data in Figure 2 are derived from 6 litters; Figure 3 derived from 24 litters; 
Figure 4, 5 and 7 derived from 6 litters each; Figure 6 derived from 6 litters. Animals were 
housed in Plexiglas cages (30x18x15cm) together with littermates and their dam for the 
whole of the experiment. Animals had access to standard chow and water ad libitum and 
bedding was wood-chips with shredded paper for nesting (Pharmaserv, France).  
 
2.2 Traumatic brain injury model and experimental procedure 
Postnatal day 7 (P7; weight 4-5g) OF1 mice (Charles River, L’Arbresle, France) of both 
sexes were randomly (alternating animals) allocated to TBI, control or TBI+ treatment 
(phosphate buffered saline [PBS] or minocycline) groups. The study protocol is detailed in 
Figure 1. A dose of 45mg/kg of minocycline was chosen based on its prior use in models of 
adult TBI, stroke and paediatric excitotoxic lesion, see Table 1. In a separate experimental 
work-space within the animal facility, mice were anesthetized with isoflurane (8% induction) 
and subjected to a closed head weight–drop head trauma at P7 in a model as described 
previously (Kaindl et al., 2007). In brief in a process lasting no more than 3 minutes, the skull 
was fixed into a stereotaxic frame, the skull surface exposed with a skin incision and the 
impact device was oriented parallel to the parietal bone with the centre of the foot plate 
(2mm diameter) positioned 2 mm anterior and 1 mm lateral to lambda on the parietal bone. 
The foot-plate was first allowed to touch the skull and was then further depressed by 0.5 
mm. The impact device consisted of a hollow stainless-steel cylinder 20 cm in length, 
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perforated at 1 cm intervals to prevent air compression, and guiding a 10 g weight falling 
from a height of 10 cm onto the foot-plate (2.0 mm in diameter). The contusion impact was 
delivered unilaterally to the left side of the skull, the same operator conducted all 
experiments and cortical contusions were of comparable severity in all animals. Body 
temperature was kept constant via the use of a heating pad maintained at 37 °C until pups 
were returned to their dams at approximately 15 minutes post-TBI.  Sham animals were 
anesthetized and an incision made in their scalp, this was then sutured and animals were 
recovered after 3 minutes in line with the time taken for the TBI procedure. Minocycline 
(45mg/kg in PBS: Sigma, Lyon, France) (Cai et al., 2006; Dommergues et al., 2003) or PBS 
alone was injected intraperitoneal immediately following TBI, and at 24 and 48 hours post-
TBI, depending on the protocol. A group of sham minocycline was not included in this study 
as the specific aim was to investigate the effects of modulating the microglial activation state 
associated with TBI. Furthermore, minocycline has been widely reported to have no effect on 
microglial gene expression in a basal state (Kobayashi et al., 2013; Scholz et al., 2015). 
 
2.3 Tissue preparation, and histology  
One or five days after TBI, animals were euthanatized via an overdose of pentobarbital and 
decapitation and brains were immersion fixed (formol 4% for 5 days), embedded in paraffin 
and coronally sectioned (16µm) from the frontal pole to the occipital lobes. Ventricular area 
was determined as described previously (Kaindl et al., 2007; Moretti et al., 2016) on cresyl-
violet-stained sections. In short, the border of each lateral ventricle from three serial sections 
spanning the hippocampus and midstriatum was outlined, then the cross-sectional 
ventricular areas were determined using ImageJ software (version 1.43; National Institute of 
Health, Bethesda, Md., USA) and the ratio between the left (ipsilateral) and right 
(contralateral) ventricular areas determined. All tissue processing and analyses were carried 
out by investigators blind to the treatment group due to coding of the brains and covering of 
the codes during analysis. There were no differences in the ventricular area of the 
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contralateral hemisphere between sham and TBI mice. Immunohistochemistry (IHC) was 
performed as previously described (Fleiss et al., 2012), and the antibodies used included: 
rabbit monoclonal anti-ionized calcium binding adaptor molecule-1 (Iba-1; 1:1000, Wako 
Chemicals USA, 019-19741), Rabbit monoclonal anti-cleaved caspase 3 (CCasp3; 1:200, 
Cell Signalling, 9661), mouse monoclonal anti-myelin basic protein (MBP; 1:500, Millipore, 
MAB382) and mouse monoclonal anti-microtubule-associated protein 2 (MAP2; 1:2000, 
Sigma, M4403). After overnight incubation with primary antibodies and washing, sections 
were incubated with appropriate secondary antibodies (1:200; Vectorlabs, California, USA).  
 
2.4 Analysis of neuropathology  
Ventricular volume was assessed by measuring the area of the ipsilateral and contralateral 
ventricles and expressed as percentage of change compared to the contralateral values. 
Iba-1-positive and CCasp3-positive cells were counted in the parietal cortex, hippocampal 
CA1 region and striatum of the traumatized hemisphere, on two images captured using a 
Leica DM6000 B microscope (Leica Microsystems Ltd.) and a 10X objective at the level of 
maximum lesion (approximately -1.50mm from bregma). Counts were carried out using 
Image J and cell numbers within a given region expressed as cells/mm2. The area of MAP2 
and MBP immunolabeling was measured at 4-6 levels per brain (one 16µm-thick serial 
section every 576µm) as previously described (Fleiss et al., 2012). Volumes of MAP2 and 
MBP immunolabeling were calculated from area measurements according to Cavalieri’s 
principle using the following formula: V = SA × P × T, where V is total volume, SA is the sum 
of the areas measured, P is the inverse of the sampling fraction and T is the section 
thickness. Volume loss was estimated by the difference in calculated volumes between the 
contralateral (right) and the ipsilateral hemispheres (left). 
 
2.5 CD11B-antibody-coupled magnetic cell isolation  
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At different time-points following TBI (2, 6, 14, 24 hours and 5 days), cells positive for 
CD11B (cluster of differentiation 11 beta, a marker for MΦ and MG), were extracted using 
the antibody-coupled magnetic bead system (MACS) following the manufacturer's 
recommendations (Miltenyi Biotec, Bergisch Gladbach, Germany) and as previously 
reported (Schang et al., 2014). In brief, the olfactory bulbs and cerebella were removed and 
the hemispheres mechanically and enzymatically digested using the Neural Tissue 
Dissociation Kit (Miltenyi Biotec, Germany). Three or four hemispheres were pooled for each 
sample to ensure sufficient RNA quantities. In a preliminary analysis, comparisons of 
MG/MΦ activation and cytokine gene expression between left and right sham hemisphere 
did not show any differences and samples were pooled. Homogenized and digested tissue 
was incubated with magnetic coupled anti-CD11B antibodies and CD11B-positive cells were 
separated in a magnetic field before being counted and frozen at -80°C. The purity of 
separated cells was assessed using quantitative real-time polymerase chain reaction (qRT-
PCR) for glial fibrillary acidic protein (GFAP; astrocytes), MBP (oligodendrocytes), neuronal 
nuclear antigen (NeuN; neurons) and CD11B (MG/MΦ), and showed levels of contamination 
less than 5%. We have described the CD11B-positive population extracted from the brain as 
MG/MΦ as we cannot exclude a contribution of macrophages to the cell population (Hsieh et 
al., 2013).  
 
2.6 RNA extraction and quantification of gene expression by real-time qPCR 
MG/MΦ qRT-PCR, primer design, and PCR setups were similar to that previously described 
(Chhor et al., 2013; Husson et al., 2005; Schang et al., 2013). In brief, RNA was extracted 
using Qiagen RNA extraction columns as per the manufacturers instructions, including initial 
homogenisation in Trizol (Invitrogen). RNA purity was verified using a nanodrop. Reverse 
transcription was performed using an iScript RT kit (Biorad) as per manufacturers 
instructions. PCR reactions were setup on a loading robot in 384 well plates with Sybr green 
from Biorad as per recommended protocol. Primer sequences are given in Table 2. Gapdh 
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(glyceraldehyde-3-phosphate dehydrogenase) was used to normalize the quantitative 
experiments based on prior reference-gene suitability testing and we verified for each 
experiment that the raw Gapdh values were not significantly different between groups. The 
relative quantities are expressed as the specific ratio between the gene of interest and the 
reference gene. Genes were classified as cytotoxic, repair/regeneration or 
immunomodulatory based on the literature (Colton and Wilcock, 2010; Ransohoff and Perry, 
2009) and previous characterization in our lab (Chhor et al., 2013).  
 
2.7 Protein extraction procedure and multiplex cytokine/chemokine assay 
Frozen cortices from 6, 14 and 24 hours post-TBI were homogenized in 0.1M PBS, and 
extracts sonicated in ice-cold homogenization buffer (3mM ethylenediaminetetraacetic acid 
[EDTA] and 1% protease inhibitor cocktail, [P8340, Sigma] in 0.1M PBS) and centrifuged 
(800xg for 10 minutes). The supernatant was collected and stored at -80°C. Protein 
concentrations were determined via a bicinchoninic acid (BCA) assay. After thawing on ice, 
supernatants were centrifuged briefly to remove particulates (300xg for 10 minutes). 
Cytokine and chemokine levels were measured using a 96-well magnetic plate assay on a 
Bio-Plex 200 according to the manufacturer's instructions (BioRad laboratories, Marnes la 
Coquette, France). Cytokines and chemokines measured included interleukins (IL) IL-1α, IL-
1β, IL-3, IL-4, IL-5, IL-6, IL-9, IL-10, IL-12(p40), IL-12(p70), IL-13, IL-17, granulocyte colony 
stimulating factor (G-CSF), interferon (IFN) γ, tumor necrosis factor (TNF) α, chemokine C-
X-C motif ligand (CXCL) 1 (KC), chemokine ligand (CCL) 2 (also known as MCP-1), CCL3 
(also known as MIP1a), CCL4 (also known as MIP1b) and CCL5 (also known as RANTES). 
All samples were run in duplicate and data analysed with Bio-Plex Manager 6.0 software. 
Cytokines and chemokines were classified as cytotoxic, repair/regeneration or 
immunomodulatory based on the literature (Colton and Wilcock, 2010; Ransohoff and Perry, 
2009) and previous characterization in our lab (Chhor et al., 2013). 
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2.8 Statistics 
Data are presented as means±SEM. No animals were excluded from any analysis. Numbers 
in each experiment are indicated within the text, or in the figure legends.  Sample sizes were 
based on calculations of effect sizes from previous studies on this model within the 
laboratory (Kaindl et al., 2007). For two experimental groups, t-tests or Mann Whitney U test 
were performed. Where more than two experimental groups were compared an ANOVA was 
performed and when this was significant (p≤0.05) a Bonferroni post-test was performed. The 
appropriate statistical test was chosen based on data normality (Kolmogorov-Smirnov test). 
The statistical test performed on each data set (using GraphPad 5.0 software [San Diego, 
CA, USA]) is indicated in the figure legend or within the text.  
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3.0 Results  
3.1 TBI increases early cell death, microglial number and cortical cytokine / 
chemokine levels  
Following TBI, CCasp3-positive cells were present in the underlying cortex, thalamic nuclei, 
hippocampal dentate gyrus, subiculum and striatum, and increased numbers of Iba-1 
positive cells were observed mainly in the underlying cortex, hippocampus and striatum, and 
a qualitative representation is found in Fig 1. Specifically for Iba-1, numbers of positive cells 
were increased in the cortex following TBI at P1 by ≈150% (contralateral 30.86±2.24 versus 
ipsilateral 46.64±2.41; n=36) and in the striatum by ≈350% (contralateral 12.05±0.77 versus 
ipsilateral 47.23±2.36; n=36). We analysed the number of Iba-1 positive cells by sex and 
found no difference between control values for the cortex (contralateral male 25.21±0.74, 
n=20 versus contralateral female 23.97±1.17, n=16; p=0.35, t-test) or striatum (contralateral 
male 11.68±1.07, n=17 versus contralateral female 12.47±1.15, n=16; p=0.55, t-test), or in 
the response to injury in the cortex (ipsilateral male 53.71±2.31, n=17 versus ipsilateral 
female 51.66±2.48, n=16; p=0.52, t-test) and striatum (ipsilateral male 47.97±3.38, n=17 
versus ipsilateral female 46.43±3.37, n=16; p=0.76, t-test). As such, we grouped males and 
females for the following analysis. The effects of TBI on the expression of 20 cytokines and 
chemokines were measured in the ipsilateral hemisphere at 6, 14 hours and 24 hours, and 
compared to levels in sham animals (Fig 2). Expression increased for markers associated 
with each MG/MΦ phenotype at all three time points. We observed that relative to levels in a 
sham hemisphere, the pro-inflammatory/cytotoxic phenotype markers IL-1β and CCL3 
(MIP1α) showed the greatest and most persistent increases in expression over time (>5 
fold). The prototypical anti-inflammatory or reparatory/regenerative cytokine IL-4 and the 
immunomodulatory cytokine IL-10 were also increased at all three time points in the 
ipsilateral hemisphere. TNFα and IL-12 (p70) were the only markers that did not significantly 
increase at any time point.  
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3.2 TBI induces MG/MΦ expression of markers of a regenerative / immunomodulatory 
phenotype  
CD11B-positive MG/MΦ were isolated from whole cortices using MACS technology at 2, 6 
and 14 hours and 1 and 5 days post-TBI, and gene expression of 12 phenotype markers 
was measured (Fig 3). Expression of the prototypical cytotoxic MG/MΦ markers CD86 and 
CD32 was decreased by TBI, and iNOS showed no increase at any time point examined. 
The cross-phenotype marker Cox-2 (cytotoxic-immunomodulatory) and IL1Rn, which has 
immunomodulatory functions, were persistently increased by TBI. Two additional 
immunomodulatory markers, SOCS3 and IL-4rα, showed early increases, but by 1-day post-
TBI were reduced to below non-TBI levels. Among the reparatory/regenerative MG/MΦ 
markers, Arg1 and Gal3 showed persistent increases following TBI, but IGF-1 and CD206 
were decreased.  
 
3.3 Blocking MG/MΦ activation with minocycline causes improvements in 
neuropathology at 1 day post-TBI 
Early brain injury was assessed via CCasp3 cell counts and using ventricular dilatation, 
calculated as the ratio of the ventricular size in the ipsilateral vs. the contralateral 
hemisphere. Animals treated with minocycline had reduced numbers of CCasp3-positive 
cells in the cortex, hippocampus and striatum (Fig 4C,D). In agreement with these data, 
minocycline treatment led to less ventricular dilatation compared with the untreated group at 
1 day post-TBI (Fig 4A,B). Sham groups treated with either vehicle or minocycline displayed 
no change in ventricular size and had very low levels of CCasp3-positive cells (data not 
shown).  
 
3.4 Improved neuropathology due to minocycline is accompanied by reduced MG 
number and altered MG/MΦ activation 
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To characterize any relationship between the MG/MΦ inflammatory response and 
neuroprotection, 1 day following TBI, MG cell numbers were quantified using Iba-1 
immunolabeling and the phenotype of isolated CD11B-positive MG/MΦ was assessed. As 
expected based on previous reports of the effects of minocycline, the numbers of Iba-1-
positive cells were decreased in the cortex, hippocampus and striatum of minocycline-
treated animals (Fig 5). Minocycline induced complex changes in the phenotype and 
cytokine/chemokine expression of MG/MΦ that were isolated post-TBI (Fig 6). The cytotoxic 
phenotype markers iNOS and IL-6 were reduced from TBI only levels by minocycline 
treatment but IL-1β was increased. Among repair/regeneration markers, treatment with 
minocycline stimulated a further increase in the expression of Gal3 and Arg1, and reduced 
the typical loss of IGF1. Among immunomodulatory markers, minocycline increased the 
expression of IL-1Rn above typical levels but led to an even greater decrease in the 
expression of IL10.  
 
3.5 Early improvements in neuropathology due to minocycline treatment are lost by 5 
days post-TBI 
Immunolabeling for MAP2 and MBP were used as surrogates for damage to neurons and 
myelination by oligodendrocytes respectively. TBI decreased the volume of tissue 
immunolabeled for MAP2 and MBP, and persistently caused ventricular dilatation in the 
injured hemisphere at 5 days post-TBI (P14; Fig 7). MAP-2 immunolabeling was similar to 
that reported previously in the immature brain (Carlsson et al., 2011; Lingwood et al., 2008), 
displaying a more diffuse pattern and with less cytoplasmic intensity than in the adult. 
Despite improvements at 1-day post-TBI, at 5 days post-TBI, in animals treated with 
minocycline, ventricle size was identical to that in PBS treated TBI animals (Fig 7A). In 
accordance with the ventricular data, the loss of MAP2 and MBP immunolabeling was not 
prevented by treatment with minocycline (Fig 7B-E). 
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     4.0 Discussion and Conclusions 
4.1 Principal results and the TBI model 
In our closed-contusion model of paediatric TBI, injury modestly increased the levels of both 
pro- and anti-inflammatory cytokines/chemokines in the brain as well as the number of MG. 
Isolated MG/MΦ had only moderate changes in gene expression, and increases specifically 
in markers for the repair/regeneration and immunomodulatory phenotypes. Blocking 
inflammation/MG/MΦ activation with minocycline decreased MG number, reduced 
expression of some pro-inflammatory cytokines but was only transiently neuroprotective.  
We chose for this study a closed-contusion weight-drop TBI model as it has injury 
mechanisms similar to those seen in paediatric TBI (Xiong et al., 2013). In particular, within 
the first 30 days of life, at 7-day old, mice display the most widespread apoptotic injury 
following TBI (Bittigau et al., 1999). This is also the period of greatest vulnerability to 
excitotoxic lesion in the rodent (Ikonomidou et al., 1989; McDonald et al., 1988) a likely 
effect of the reduced compensatory anti-oxidant defences of the immature as opposed to the 
adult brain (Fan et al., 2003). As apoptotic cell death, excitotoxicity and oxidative stress play 
crucial roles in the pathogenesis of TBI in the neonate (Ruppel et al., 2001; Zhang et al., 
2005); this adds weight to the relative usefulness of modelling TBI at this period of rodent 
development.  
 
4.2 Cortical tissue damage and injury response following paediatric TBI.  
Following TBI we observed increased total cortical expression of cytokines and chemokines, 
as well as dilated ventricles and obvious tissue injury in the thalamus and hippocampus of 
the injured hemisphere. These observations are generally in agreement with previous 
reports from this model and TBI in large animal models and humans (Helmy et al., 2011; 
Kaindl et al., 2007; Moretti et al., 2016; Xiong et al., 2013). Specific comparisons across 
studies are hampered by differences in models and methods, specifically the use of protein 
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versus gene analysis. However, specific comparisons for gene expression can be made to 
published gene array data. In this context levels of almost all of the jointly reported cytokines 
and chemokines are considerably lower in our model than that previously reported in two 
adult rat models of controlled cortical impact (Matzilevich et al., 2002; Raghavendra Rao et 
al., 2003; White et al., 2013), and one  rat model of fluid-percussion injury (Truettner et al., 
2005), but were comparable to that reported in a model of adult rat bilateral prefrontal 
cortical contusion (He et al., 2004).  Protein levels for chemokines and cytokines are also 
consistently and persistently high in previous reports from adult models of contusion and 
blast-induced TBI (Bye et al., 2007; He et al., 2004; Kumar et al., 2015; Williams et al., 
2007). We suggest that further work is needed to ascertain if any smaller magnitude of 
cortical pro-inflammatory cytokine release is linked to our observation that neonatal TBI 
induces a predominantly reparatory/regenerative or immunomodulatory MG/MΦ phenotype. 
As MG/MΦ are the chief drivers of neuroinflammation, a predominantly anti-inflammatory 
response might prevent cortical inflammation reaching the levels seen in adult injury models, 
in which there is a robust cytotoxic/pro-inflammatory MG profile (Kumar et al., 2015).  
We also wish to briefly discuss the effects of TBI in the contralateral hemisphere. We noted 
that gene expression was lower than sham level even in the contralateral hemisphere in 
MG/MΦ for cytotoxic markers (including CD86 and CD32) and also for the repair-
regeneration marker CD206 and the immunomodulatory marker SphK1. This type of remote 
gene expression change has been previously reported in an adult cortical contusion model 
where it was reported that these are not simply reduced magnitude changes spilling over 
from the ipsilateral cortex but that some effects are specific (White et al., 2013). Remote 
tissue changes (such as in the cortex following spinal cord injury) are considered to be 
crucial mediators of sensorimotor dysfunction and cognitive impairments (Ajao et al., 2012; 
Kamper et al., 2013; Kim et al., 2006). The diffusion of inflammatory products setting up a 
chain reaction, signalling via gap junctions in astrocytes and changes in neuronal activity 
patterns in distant areas are hypothesized to underpin these remote effects. Disruption of the 
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developmental functions of MG (such as synaptogenesis) is considered to underpin some of 
the injury associated with damage to the immature brain at the injury site and in the remote 
regions, see (Tremblay et al., 2011). Furthermore, on going changes in homeostatic 
functions are associated with neurodegeneration such as in aging (Grabert et al., 2016; 
Griffin et al., 2006; Hart et al., 2012; Lourbopoulos et al., 2015). As such, additional 
longitudinal studies in this model are warranted to explore the remote and persisting effects 
of TBI.  
 
4.3 MG/MΦ phenotype in paediatric vs. adult TBI and other injury models 
This is the first study to assess the phenotype of ex-vivo MG/MΦ over such a 
comprehensive time course (and with so many markers) after an acute neonatal injury. 
However, there are interesting temporal studies on isolated MG in an adult TBI model 
(Kumar et al., 2015), and total cortical inflammation in an adult TBI model (Wang et al., 
2013) although the methods of analysis vary making it difficult to directly compare data. 
However, in adult TBI, the protein expression of ex vivo MG for classical pro-inflammatory 
markers increased over time such that at +5 days all markers were robustly increased, 
compared to our gene expression data wherein only three cytotoxic markers were 
moderately increased, with no cohesive time point of change. The authors of the adult TBI 
study sought to describe the robust predominantly pro-inflammatory or mixed phenotype that 
replaced a transient but specific repair/regeneration and immunomodulatory phenotype as 
"Mtran" (Kumar et al., 2015). In our paediatric model, since cytotoxic MG/MΦ gene 
expression was generally low, including at 5 days post-TBI, we conclude it is unlikely that 
this phenotype occurs in this model, although we would need to validate our data with the 
same FACS based protein analysis. However, when comparing neonatal and adult studies it 
is worth considering that robust age-dependent differences in MG/MΦ gene expression have 
been reported (Bennett et al., 2016; Butovsky et al., 2014). In brief, the stage of 
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development is likely important for MG/MΦ reactivity and is an important consideration for 
studies of neuroinflammation.  
Another key point in the interpretation of these data is the ability of cells to co-express 
markers, reflecting the in vivo complexity of phenotype descriptors. Our gene expression 
analysis dose not allow up to determine if there are discrete populations of cells switching 
phenotype or cell co-expressing different category marker as has been previously reported 
in adult studies (Bedi et al., 2013; Li et al., 2014; Vogel et al., 2013). Co-expression pattern 
are likely in our paediatric TBI model, but from the paucity of gene expression changes 
overall any robust co-expression of markers seems unlikely.   
 
4.4 Mode of action of minocycline as a neuroprotective agent 
Minocycline is a second-generation semi-synthetic tetracycline that is best known for 
reducing pro-inflammatory responses via its effects on MG/MΦ (Homsi et al., 2010; 
Kobayashi et al., 2013; Ng et al., 2012). Minocycline has been used successfully to reduce 
brain damage across a diverse range of injury/disease models, such as multiple sclerosis 
(experimental autoimmune encephalitis), term and preterm brain injury (excitotoxicity and 
hypoxia-ischemia, respectively) and Alzheimer’s disease, for review see (Garrido-Mesa et 
al., 2013). Minocycline successfully reduced TBI severity at our early time point of 1 day 
post-lesion, despite there being little pro-inflammatory response from MG/MΦ. It is not clear 
from the literature whether minocycline can act directly on astrocytes (Kernt et al., 2010; 
Yoon et al., 2012) to facilitate any effect. Nevertheless, several pathological mechanisms 
involved in TBI are counteracted by minocycline, possibly accounting for the 
neuroprotection. These include that minocycline increases levels of the anti-apoptotic protein 
Bcl-2 (Wang et al., 2004) and the chelation of magnesium and calcium (Gonzalez et al., 
2007) and also decreases activation of MMPs (Koistinaho et al., 2005) and caspase-1 and 
caspase-3 (Sanchez Mejia et al., 2001). The protective effect of inhibiting MMPs in this 
model of paediatric TBI has been previously demonstrated (Sifringer et al., 2007).  
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4.5 Reasons for absence of long-term neuroprotection by minocycline 
This study is not the first to report a limited neuroprotective effect of minocycline (Fernandez-
Gomez et al., 2005; Fox et al., 2005; Sriram et al., 2006; Yang et al., 2003). Of particular 
interest is a transient neuroprotective effect reported in an adult closed-contusion TBI model 
that is strikingly similar to what we observed. In this adult TBI model, behavioural 
improvements and reduced lesion volume at 1-day post-TBI were lost by 4 days post-TBI 
(Bye et al., 2007). An early but transient therapeutic effect of minocycline has also been 
reported following hypoxic-ischemic injury in the mouse (Fox et al., 2005; Nijboer et al., 
2010), indicating that this effect of minocycline is not specific to TBI.  A limitation of these 
previous studies and our current study is that we did not test whether behavioural outcomes 
were improved, despite no change in neuropathology. The concept of a protective phase of 
the MG/MΦ response after injury has gained enormous support from studies of adult and 
neonatal models (Faustino et al., 2011; Hernandez-Ontiveros et al., 2013; Hu et al., 2012; 
Lalancette-Hebert et al., 2007)., We speculate that the lack of persistent neuroprotection 
with minocycline in this model might be because microglia are attempting to repair the brain. 
As such, there are short-term positive effects (that might relate to positive effects of 
minocycline on other cells{Koistinaho, 2005 #1326}), but when MG are prevented from 
attempting to repair the brain in the longer term due to exposure to minocycline these 
positive gains are neutralised by 5 days. What is apparent however is that as outlined in a 
(non exhaustive) list of studies in Table 1 there are unclear influences on outcome of species 
(rat versus mouse) and treatment regime (immediate/early only, versus immediate and 
continuing). The multitude of differences in experimental conditions and outcome measures 
preclude any firm conclusions on the influences of these factors on the true neuroprotective 
ability of minocycline. 
 
4.6 Conclusions 
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In summary, despite cortical inflammation and cell death following TBI, MG/MΦ retain the 
expression of markers of an endogenous repair and regenerative phenotype in this model. 
Also, there are only moderate increases in total cortical inflammatory markers compared to 
adult injury models. We identified that using minocycline to modify the activity of MG/MΦ had 
positive early effects on injury, but did not persistently improve outcome. This work adds 
considerably to our understanding of neuroinflammation after TBI in a neonatal model by 
suggesting that further therapy design should focus on supporting repair and regeneration 
type MG/MΦ activation states rather than blanket immunosuppression.  
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FIGURE 1. 
Schematic representation of the experimental procedures including administration of 
drugs and tissue collection, and injury distribution. Injury is indicated by the expression 
of CCasp3 at 1 day (+1d) and 5 days (+5d) following TBI. Slightly increased areas of 
labelling shown by orange stars, moderate increases by red stars and intense changes 
shown as blocks of red.   
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FIGURE 2. Expression of cytokines and chemokines from the ipsilateral hemisphere 
over time post-TBI. Genes are grouped based on predicted role in inflammation: cytotoxic 
(CytoT), reparatory/regenerative (R-Regen), and immunomodulatory (Immu-M) based on 
(Colton, 2009; Prinz et al., 2011). Data are normalized to sham group expression (Sham=1) 
and are indicated as means±SEM (n=6-8 animals/group). Data were compared to the 
corresponding sham group using a Mann-Whitney U test. *, p<0.05. **, p<0.01. ***, p<0.001. 
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FIGURE 3. Expression of phenotype markers by MG/MΦ isolated at various times 
post-TBI. Genes are grouped based on predicted role in inflammation: cytotoxic, 
reparatory/regenerative (R-Regen), and immunomodulatory (ImmunoM) based on (Colton, 
2009; Prinz et al., 2011). Data are normalized to sham group expression (Sham=1) and are 
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means±SEM (n=5-6 animals/group). Gene expression over time was analysed with a two 
way repeated measures ANOVA, with a Bonferroni post-test to compare the relative 
expression for each hemisphere at each time point. Summary of the ANOVA results are 
presented on each panel (effects of interaction between variable [INTx], effects of time 
[TIME] and effects of TBI [HEMI]. Results of the post-test are indicated with:  *, p<0.05. **, 
p<0.01. **,. ***, p<0.001.   
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FIGURE 4. Minocycline improves neuropathology 1-day post-TBI. A) Quantification of 
ventricular volume at 1 day post-TBI, and B) representative images of cresyl-violet-stained 
sections from both groups indicating ventricular size.  C) Quantification of CCasp-3-positive 
cell number. D) Representative images of CCasp-3 immunolabeling in the striatum from both 
groups, scale bar 50µm. Data are indicated by means±SEM (n=9-18 animals/group), and 
PBS- and minocycline-treated groups were compared via a Student’s t-test. *, p<0.05. **, 
p<0.01.  
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FIGURE 5. Minocycline decreases MG cell number 1-day post-TBI.  A) quantification of 
the number of Iba-1-positive cells at 1 day following TBI in PBS- and minocycline-treated 
mice within the cortex, hippocampus and striatum. B) Representative Iba-1-positive cells in 
animals from each group from within the striatum, scale bar 50µm. Data are indicated by 
means ±SEM (n=9-16 animals/group). PBS- and minocycline-treated groups were compared 
via a Student’s t-test. *, p<0.05.  
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FIGURE 6. Effects of minocycline treatment on the expression of phenotype markers 
from MG/MΦ isolated 24 hours post-TBI. Data are shown normalized to expression in a 
sham group (Sham=1) and as means±SEM (n=9-16 animals/group). Genes are grouped 
based on predicted role in inflammation: cytotoxic, reparatory/regenerative (R-Regen), and 
immunomodulatory (Immu-M) based on (Colton, 2009; Prinz et al., 2011). Data were 
compared with a two way ANOVA, with a Bonferroni post-test to compare the relative 
expression for each hemisphere (PBS versus TBI). Summary of the ANOVA results are 
presented on each panel (effects of interaction between variable [INTx], effects of time 
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[TIME] and effects of TBI [HEMI]. Results of the post-test comparing each hemisphere are 
indicated with:  *, p<0.05. **, p<0.01. **,. ***, p<0.001.  .   
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FIGURE 7. Lack of improvement in neuropathology in minocycline treated animals 5 
days post-TBI. A) Quantification of ventricular size 5 days post-TBI and B) quantification of 
the volume of tissue loss in the traumatized hemisphere 5 days post-TBI based on MAP-2 
immunoreactivity, D) representative photomicrographs of MAP2-immunolabeled sections, 
scale bar 50µm. C) and E) quantification and representative images of the volume of white 
matter loss in the traumatized hemisphere based on MBP immunoreactivity, scale bar 
200µm. Data are indicated by means±SEM (n=12-18 animals/group). PBS- and minocycline-
treated groups were compared via a Student’s t-test. 
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Table 1: Summary of selected studies investigating the neurotherapeutic effects of minocycline  
Study Animal Injury Dose Regime Cell death / Lesion Volume MG number Outcome  
Dommerg
ues et al. 
(2003) 
P5 
mouse 
Excitotoxic  45 
mg/kg Twice daily from P5-P7 
Decreased Cleaved Caspase-
3 at +1 day and decreased 
lesion volume at +5 days 
Decreased numbers of 
Lectin+ MG 
Decreased lesion volume at +5 
days  
Fox et al. 
(2005) P7 rat MCAO 45mg/kg +2h & +2h, or +8h & +18h 
Decreased lesion volume at 
+1 day 
No change in ED1+ MG 
numbers 
No improvement in lesion volume 
at +7 days  
Yang et al. 
(2015) 
Adult 
rat MCAO 5mg/kg +5 min Decreased infarct on MRI 
60% decreased (Increased 
anti-inflammatory type MG) Improvements on MRI at 4 week  
Cai et al. 
(2006) P4 rat HI 45mg/kg 
12h before, immediately after & 
daily for 3 days 
Decreased pyknosis at  +4 
days 
50% decrease in numbers of 
lectin positive MG 
Decreased loss of mature 
oligodendrocytes and myelin at 
+2 weeks  
Lechpam
mer et al. 
(2008) 
P6 rat HI 50mg/kg Immediately following HI Decreased white matter injury at +3 days 
Decreased numbers of CD68+ 
& MHCII+ cells at +3 days   
Arvin et al. 
(2002) P7 rat HI 
22.5-
45mg/kg Immediately before or +3h 
Decreased lesion volume at 
+7 days - 
Decreased lesion volume at +7 
days  
Tsuji et al. 
(2004) 
P7 
mouse 
HI 
22-135 
mg/kg 
(1) Twice in first 24h (45mg/kg) & 
twice in the next 24h (23mg/kg), or 
(2) Twice in first 24h (135mg/kg) & 
twice in the next 24h (68mg/kg), or 
(3) Single dose 12h before HI 
(45mg/kg) 
Exacerbated total injury score 
for all treatments (1-3) at +7 
days 
- 
Mouse: Exacerbated total injury 
score for all treatments (1-3) at +7 
days  
P7 rat 45 mg/kg 
(4) Immediately before HI, or 
(5) 12h before HI 
Decreased total injury score 
for both treatments (4-5) at +7 
days 
- 
Rat: Decreased total injury score 
for both treatments (4-5) at +7 
days  
Hanlon et 
al. (2016) P11 rat 
Repeated 
TBI (CCI) 45mg/kg 
Once immediately after the third 
and final TBI 
No change in fluro-jade B+ 
cell number at +3, +7 & +21 
days 
No change 
Exacerbated defects in retention 
tasks. No improvements in tissue 
loss or spatial memory defects at 
+21 days.  
 
Bye et al. 
(2007) 
Adult 
mouse 
TBI (CCI) 45 
mg/kg +30 min & every 12h for 3 days 
Decreased at +1 day, no 
change at +4 days 
Decreased amoeboid ED1+ 
MG 
No improvement in motor function 
at +1 week  
Homsi et 
al. (2010) 
Adult 
mouse 
TBI (CCI) 
 
90-
45mg/kg 
+5 min (90mg/kg), +3h & +9h 
(45mg/kg) 
50% decrease in cortical 
tissue loss 
50% Decrease in CD11b+ 
MG/MΦ 
Improvement in locomotor 
hyperactivity at +8 weeks  
Current 
study 
P7 
mouse TBI (WD) 45mg/kg Immediately after & at +24h & +48h 
Decreased cleaved caspase-
3+ cell numbers, decreased 
ventricular volume at +1 day 
15% decrease in numbers of 
Iba1+ MG (minimal change in 
activation by gene expression) 
No improvements in 
neuropathology at +5 days  
HI, hypoxic/ischemic. CCI, controlled cortical impact. WD, weight drop 
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Table 2: Primer sequences and NCBI references 
Gene Sense Antisense NCBI Reference 
Gapdh GGC CTT CCG TGT TCC TAC TGT CAT CAT ATC TGG CAG GTT NM_008084.2 
iNos CCC TTC AAT GGT TGG TAC ATG G ACA TTG ATC TCC GTG ACA GCC NM_010927.3 
CD32 CTG GAA GAA GCT GCC AAA AC CCA ATG CCA AGG GAG ACT AA NM_010187.2 
CD86 GAG CGG GAT AGT AAC GCT GA GGC TCT CAC TGC CTT CAC TC NM_019388.3 
Ptgs2 TCA TTC ACC AGA CAG ATT GCT AAG CGT TTG CGG TAC TCA TT NM_011198.3 
CD206 CTT CGG GCC TTT GGA ATA AT TAG AAG AGC CCT TGG GTT GA NM_008625.2 
Arg1 GTG AAG AAC CCA CGG TCT GT GCC AGA GAT GCT TCC AAC TG NM_007482.3 
Lgals3 GAT CAC AAT CAT GGG CAC AG ATT GAA GCG GGG GTT AAA GT NM_010705.3 
Igf1 TGG ATG CTC TTC AGT TCG TG GCA ACA CTC ATC CAC AAT GC NM_010512.4 
Sphk1 TCC AGA AAC CCC TGT GTA GC CAG CAG TGT GCA GTT GAT GA NM_001172475.1 
Il1rn TTG TGC CAA GTC TGG AGA TG TTC TCA GAG CGG ATG AAG GT NM_031167.5 
Il4ra GGA TAA GCA GAC CCG AAG C ACT CTG GAG AGA CTT GGT TGG NM_001008700.3 
Socs3 CGT TGA CAG TCT TCC GAC AA TAT TCT GGG GGC GAG AAG AT NM_007707.3 
IL1b GGG CCT CAA AGG AAA GAA TC TCT TCT TTG GGT ATT GCT TGG NM_008361.3 
IL-6 CAA AGC CAG AGT CCT TCA GA GCC ACT CCT TCT GTG ACT CC NM_031168.1 
IL10 CTC CCC TGT GAA AAT AAG AGC GCC TTG TAG ACA CCT TGG TC NM_010548.2 
IL-12a TCA CAA CCA TCA GCA GAT CA TGC AGA GCT TCA TTT TCA CTC NM_001159424.1 
IL-12b ATC CAG CGC AAG AAA GAA AA AAT AGC GAT CCT GAG CTT GC NM_008352.2 
IL-18 TTC GTT GAC AAA AGA CAG CC TAT CAG TCT GGT CTG GGG TTC NM_008360.1 
Tnfa GCC TCT TCT CAT TCC TGC TT AGG GTC TGG GCC ATA GAA CT NM_013693.3 
Cxcl1 GCA CCC AAA CCG AAG TCA TA AGG TGC CAT CAG AGC AGT CT NM_008176.3 
Cxcl10 GGG TAA AGG GAG GTG GAG AG GCT TAT TGA AAG CGG TGA GC NM_021274.2 
Ccl2 CAT CCA CGT GTT GGC TCA TCA TTG GGA TCA TCT TGC TG NM_011333.3 
Ccl3 TTT TGA AAC CAG CAG CCT TT CTG CCT CCA AGA CTC TCA GG NM_011337.2 
Mbp CCG GAC CCA AGA TGA AAA C CTT GGG ATG GAG GTG GTG T NM_010777.3 
Gfap CTC CTG GTA ACT GGC CGA CT AAG CCA AGC ACG AAG CTA AC NM_010277.3 
NeuN CGA TGC TGT AGG TTG CTG TG CAG ATA TGC TCA GCC AGC AG NM_001039168.1 
CD11B CTG GTG CTC TTG GCT CTC AT GGC AGC TTC ATT CAT CAT GT NM_001082960.1 
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Highlights 
• TBI in neonates leads to tissue loss and microglia/macrophage activation over several days 
• Microglia/macrophage are predominantly of a reparatory/regenerative or immunomodulatory 
type after neonatal TBI 
• Microglia/macrophage inhibition (using minocycline) after TBI is only transiently 
neuroprotective 
 
 
